Diagnostic value of ICTP for bone metastases of lung cancer: a meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

LANG Jiangli ¹ , ZHAO Qian ² ,  YU Xijie ¹

1. Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
2. Department of General Practice, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding?author：

YU Xijie, Email: xijieyu@hotmail.com

Keywords：

ICTP; Lung cancer; Bone metastases; Diagnostic value; Meta-analysis; Systematic review

DOI：

10.7507/1672-2531.201711055

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectivesTo systematically review the value of cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) in the diagnosis of bone metastases of lung cancer.MethodsThe Cochrane Library, PubMed, EMbase, WanFang Data and CBM databases were electronically searched to collect studies on ICTP in the diagnosis of lung cancer bone metastases from inception to November 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies by QUADAS-2 standard. Meta-analysis was performed by using Meta-Disc 1.4 software.ResultsA total of 8 studies involving 781 patients were included. The results of meta-analysis showed that the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnosis odds ratio and area under the curve of summary receiver operating characteristics were 71% (95%CI 0.65 to 0.76), 80% (95%CI 0.76 to 0.84), 3.79 (95%CI 2.31 to 6.21), 0.35 (95%CI 0.25 to 0.49), 14.67 (95%CI 6.99 to 30.81) and 0.860 3, respectively.ConclusionsICTP cooperate with imaging tests may be accurate and practical in diagnosis of bone metastases of lung cancer. Due to the limited quality and quantity of included studies, the above results should be validated by more studies.

Citation： LANG Jiangli, ZHAO Qian, YU Xijie. Diagnostic value of ICTP for bone metastases of lung cancer: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2018, 18(8): 816-821. doi: 10.7507/1672-2531.201711055 Copy

1.	Sunaga T, Shimamoto K, Nakamura S, et al. The association between fever and prognosis in lung cancer patients with bone metastases receiving zoledronic acid. Chemotherapy, 2017, 62(6): 327-333.
2.	da Silva GT, Bergmann A, Thuler LCS. Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer. Support Care Cancer, 2016, 24(2): 731-736.
3.	Huang J, Gu T, Ying J. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer. Int J Clin Oncol, 2017, 22(6): 1015-1025.
4.	Zhang Y, Yi M, Cao J, et al. Serum cross-linked N-telopeptide of type I collagen for the diagnosis of bone metastases from solid tumours in the Chinese population: meta-analysis. J Int Med Res, 2016, 44(2): 192-200.
5.	Roato I. Bone metastases: When and how lung cancer interacts with bone. World J Clin Oncol, 2014, 5(2): 149-155.
6.	Liu L, Chen X, Wang Y, et al. Notch3 is important for TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1. Cancer Gene Ther, 2014, 21(9): 364-372.
7.	Tang C, Liu Y, Qin H, et al. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Clin Chim Acta, 2013, 426: 102-107.
8.	Izumi M, Nakanishi Y, Takayama K, et al. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer, 2001, 91(8): 1487-1493.
9.	章火祥, 謝鑫友, 于小妹, 等. 血清 Ⅰ 型膠原吡啶交聯終肽、骨鈣素在腫瘤骨轉移中的應用. 國際檢驗醫學雜志, 2008, 29(11): 983-985.
10.	張世強, 陳冬波, 王保慶, 等. 肺癌患者血清 NTx、ICTP 和 BAP 水平與骨轉移的相關性研究. 臨床腫瘤學雜志, 2011, 16(6): 534-537.
11.	Nakamura H, Kashiwabara K, Yagyu H, et al. Assisted diagnosis of lung cancer metastasis to the bone using a bone absorption marker. Japan J Lung Cancer, 1998, 38(2): 123-130.
12.	Toyama K. Bone metabolic markers in the diagnosis and monitoring of bone metastasis from lung cancer. J Med Society Toho University, 2004, 51(1): 18-25.
13.	Yokoyama T, Yamamoto M, Shima K, et al. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer. Respirology, 2005, 10(3): 300-304.
14.	Zissimopoulos A, Stellos K, Matthaios D, et al. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J Buon, 2009, 14(3): 463-472.
15.	鄒小農, 賈漫漫, 王鑫, 等. 中國肺癌和煙草流行及控煙現狀. 中國肺癌雜志, 2017, 20(8): 505-510.
16.	王明睿, 蔣電明. Ⅰ 型膠原吡啶交聯終肽在腫瘤骨轉移中的臨床意義. 中華檢驗醫學雜志, 2012, 35(6): 574-576.
17.	高云, 方健, 劉敘儀, 等. 305例非小細胞肺癌骨轉移的診斷、治療及預后分析. 中國肺癌雜志, 2006, 9(4): 357-361.
18.	陳孟權, 周永列, 余細平, 等. 骨代謝標志物組合模型對診斷肺癌骨轉移的價值. 中國衛生檢驗雜志, 2016, 26(18): 2648-2651.
19.	Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem, 1999, 45(8 Pt 1): 1240-1247.
20.	Ylisirni? S, Sassi ML, Risteli J, et al. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res, 1999, 19(6C): 5577-5581.

1. Sunaga T, Shimamoto K, Nakamura S, et al. The association between fever and prognosis in lung cancer patients with bone metastases receiving zoledronic acid. Chemotherapy, 2017, 62(6): 327-333.
2. da Silva GT, Bergmann A, Thuler LCS. Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer. Support Care Cancer, 2016, 24(2): 731-736.
3. Huang J, Gu T, Ying J. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer. Int J Clin Oncol, 2017, 22(6): 1015-1025.
4. Zhang Y, Yi M, Cao J, et al. Serum cross-linked N-telopeptide of type I collagen for the diagnosis of bone metastases from solid tumours in the Chinese population: meta-analysis. J Int Med Res, 2016, 44(2): 192-200.
5. Roato I. Bone metastases: When and how lung cancer interacts with bone. World J Clin Oncol, 2014, 5(2): 149-155.
6. Liu L, Chen X, Wang Y, et al. Notch3 is important for TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1. Cancer Gene Ther, 2014, 21(9): 364-372.
7. Tang C, Liu Y, Qin H, et al. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Clin Chim Acta, 2013, 426: 102-107.
8. Izumi M, Nakanishi Y, Takayama K, et al. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer, 2001, 91(8): 1487-1493.
9. 章火祥, 謝鑫友, 于小妹, 等. 血清 Ⅰ 型膠原吡啶交聯終肽、骨鈣素在腫瘤骨轉移中的應用. 國際檢驗醫學雜志, 2008, 29(11): 983-985.
10. 張世強, 陳冬波, 王保慶, 等. 肺癌患者血清 NTx、ICTP 和 BAP 水平與骨轉移的相關性研究. 臨床腫瘤學雜志, 2011, 16(6): 534-537.
11. Nakamura H, Kashiwabara K, Yagyu H, et al. Assisted diagnosis of lung cancer metastasis to the bone using a bone absorption marker. Japan J Lung Cancer, 1998, 38(2): 123-130.
12. Toyama K. Bone metabolic markers in the diagnosis and monitoring of bone metastasis from lung cancer. J Med Society Toho University, 2004, 51(1): 18-25.
13. Yokoyama T, Yamamoto M, Shima K, et al. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer. Respirology, 2005, 10(3): 300-304.
14. Zissimopoulos A, Stellos K, Matthaios D, et al. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J Buon, 2009, 14(3): 463-472.
15. 鄒小農, 賈漫漫, 王鑫, 等. 中國肺癌和煙草流行及控煙現狀. 中國肺癌雜志, 2017, 20(8): 505-510.
16. 王明睿, 蔣電明. Ⅰ 型膠原吡啶交聯終肽在腫瘤骨轉移中的臨床意義. 中華檢驗醫學雜志, 2012, 35(6): 574-576.
17. 高云, 方健, 劉敘儀, 等. 305例非小細胞肺癌骨轉移的診斷、治療及預后分析. 中國肺癌雜志, 2006, 9(4): 357-361.
18. 陳孟權, 周永列, 余細平, 等. 骨代謝標志物組合模型對診斷肺癌骨轉移的價值. 中國衛生檢驗雜志, 2016, 26(18): 2648-2651.
19. Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem, 1999, 45(8 Pt 1): 1240-1247.
20. Ylisirni? S, Sassi ML, Risteli J, et al. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res, 1999, 19(6C): 5577-5581.

Chinese Journal of Evidence-Based Medicine

Diagnostic value of ICTP for bone metastases of lung cancer: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content